

This application is a continuation-in-part of U.S. Patent Application No. 09/443,686, filed November 18, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/352,616, filed July 13, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/288,946, filed April 9, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/232,149, filed January 15, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/159,812, filed September 23, 1998, which is a continuation-in-part of U.S. Patent Application No. 09/115,453, filed July 14, 1998, which is a continuation-in-part of U.S. Patent Application No. 09/030,607, filed February 25, 1998, which is a continuation-in-part of U.S. Patent Application No. 09/020,956, filed February 9, 1998, which is a continuation-in-part of U.S. Patent Application No. 08/904,804, filed August 1, 1997, which is a continuation-in-part of U.S. Patent Application No. 08/806,099, filed February 25, 1997.

In the Claims:

Please cancel claims 66-71.

Please amend claim 72 to read as follows:

72. (Amended) A composition comprising an immunostimulant and an isolated polypeptide having at least 90% identity to the entirety of SEQ ID NO: 525, wherein the polypeptide contains an amino acid sequence capable of stimulating human T-cells.

Please add new claims 73-78 set forth below.

73. (New) A composition comprising an immunostimulant and an isolated polypeptide having at least 90% identity to a polypeptide comprising amino acids 1-39 of SEQ ID NO: 525, wherein the polypeptide contains an amino acid sequence capable of stimulating human T-cells.

74. (New) A composition comprising an immunostimulant and an isolated polypeptide comprising SEQ ID NO: 525, wherein the polypeptide contains an amino acid sequence capable of stimulating human T-cells.